Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06891196 · ClinicalTrials.gov registry record

Mixed-Methods Evaluation of Short-, Medium-, and Long-Term Outcomes Following Hip Treatment

A clinical trial of Hip Dysplasia and Avascular Necrosis of Hip, sponsored by Mayo Clinic.

Active
Registry status
500
Enrollment target
1
Study location

NCT06891196: Active study of Hip Dysplasia and Avascular Necrosis of Hip, sponsored by Mayo Clinic.

NCT06891196 is a study of Hip Dysplasia and Avascular Necrosis of Hip that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 500 participants, above the 107-participant average among 5 other Hip Dysplasia trials with a reported enrollment target (367% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06891196, a study of Hip Dysplasia and Avascular Necrosis of Hip, is active but no longer recruiting, sponsored by Mayo Clinic.

ACTIVE NOT RECRUITING
Registry status
500 participants
Enrollment target
1
Study location

Study Summary

This study, titled "Mixed-Methods Evaluation of Short-, Medium-, and Long-Term Outcomes Following Hip Treatment," aims to assess the long-term effectiveness of treatments for pediatric hip conditions, including hip dysplasia, Legg-Calve-Perthes disease, SCFE, and avascular necrosis.

Primary Outcome

Total number of patients who required revision surgery for pediatric hip conditions

Interventions

  • OTHER Long-term Follow-up Surveys

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2025-01-15
Est. Completion 2026-01-15
Mayo Clinic

2,844 total trials

What the registry record for NCT06891196 still lists

NCT06891196 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 107-participant average among 5 other Hip Dysplasia trials with a reported enrollment target (367% higher).

The record links to 3 conditions, with Hip Dysplasia appearing as the primary indexed condition, and to 1 intervention - of which Long-term Follow-up Surveys is the first listed.

NCT06891196 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT06891196 about?

NCT06891196 is a clinical study titled "Mixed-Methods Evaluation of Short-, Medium-, and Long-Term Outcomes Following Hip Treatment". This study, titled "Mixed-Methods Evaluation of Short-, Medium-, and Long-Term Outcomes Following Hip Treatment," aims to assess the long-term effectiveness of treatments for pediatric hip conditions, including hip dysplasia, Legg-Calve-Perthes disease, SCFE, and avascular necrosis.

What is the current status of trial NCT06891196?

This trial is currently active not recruiting. The enrollment target is 500 participants. The study started on 2025-01-15. Estimated completion is 2026-01-15.

What conditions does trial NCT06891196 study?

This clinical trial studies the following conditions: Hip Dysplasia, Avascular Necrosis of Hip, Legg-Calvâe-Perthes Disease.

What interventions are being tested in trial NCT06891196?

The interventions under investigation include: Long-term Follow-up Surveys (OTHER).

Who is sponsoring clinical trial NCT06891196?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06891196 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hip Dysplasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001230 · 500 participants

    Host Response to Infection and Treatment in Filarial Diseases

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06891196, the US trial registry maintained by the National Library of Medicine. NCT06891196 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.